Drugs for Anaplastic Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 197)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Dabrafenib |
Approved, Investigational |
Phase 4 |
|
1195765-45-7 |
44462760 |
Synonyms:
DABRAFENIB
DRB436
GSK2118436
GSK-2118436
|
GSK2118436|GSK2118436A|Tafinlar®
GSK2118436a
GSK-2118436A
TAFINLAR
|
|
2 |
|
Procarbazine |
Approved, Investigational |
Phase 3 |
|
671-16-9 |
4915 |
Synonyms:
1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine
2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine
4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide
Cambridge laboratories brand OF procarbazine hydrochloride
Hydrochloride, procarbazine
Ibenzmethyzin
Ibenzmethyzine
IBZ
Matulane
MBH
MIH
Monohydrobromide, procarbazine
Monohydrochloride, procarbazine
N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide
N-4-Isopropylcarbamoylbenzyl-n'-methylhydrazine
Natulan
N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide
N-Isopropyl-a-(2-methylhydrazino)-p-toluamide
N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide
|
N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide
N-Isopropyl-α-(2-methylhydrazino)-p-toluamide
p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
PCX
Procarbazin
Procarbazina
PROCARBAZINE
Procarbazine hydrochloride
Procarbazine monohydrobromide
Procarbazine monohydrochloride
Procarbazinum
RO-4-6467
RO-4-6467 FREE BASE
RO-4-6467/1
RO-4646711
Roche brand OF procarbazine hydrochloride
Sigma tau brand OF procarbazine hydrochloride
Sigma-tau brand OF procarbazine
Sigma-tau brand OF procarbazine hydrochloride
|
|
3 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
4 |
|
Tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
5 |
|
Valproic acid |
Approved, Investigational |
Phase 3 |
|
99-66-1 |
3121 |
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 Propylpentanoic acid
2-N-PROPYL-4-PENTENOIC ACID
2-N-Propyl-N-valerate
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-Propylpentanoic acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-Propylvaleric acid
44089
4-Heptanecarboxylate
4-Heptanecarboxylic acid
A-44090
A-44090|Depakote®|Epilim®|valproate sodium
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acido valproico
ácido valproico
Acidum valproicum
Alti-valproic
Apo-divalproex
Apo-valproic
Apo-valproic syrup
Avugane
Baceca
Calcium valproate
Calcium, valproate
Convulex
Convulsofin
Delepsine
Depacon
Depakene
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Deproic
Di-N-propylacetate
Di-N-propylacetic acid
Di-N-propylessigsaeure
Di-N-propylessigsaure
Di-n-propylessigsäure
Dipropyl acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DOM-divalproex
Dom-valproate
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
Epiject i.v.
Epilex
Epilim
|
Epival
Epival er
Ergenyl
Gen-divalproex
Kyselina 2-propylvalerova
LEP321
Magnesium valproate
Med valproic
Mylproin
Myproate
Myproic acid
N-Dipropylacetic acid
N-DPA
Novo-divalproex
Novo-valproic
Novo-valproic - ecc
Novo-valproic soft gel cap
NSC-93819
Nu-valproic
PEAC
Penta-valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
Ratio-valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
Sandoz valproic
Savicol
Semisodium valproate
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
Sprinkle
STAVZOR
Valcote
Valparin
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
VALPROIC ACID
Valproic acid usp
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
|
|
6 |
|
Eflornithine |
Approved, Withdrawn |
Phase 3 |
|
70052-12-9 |
3009 |
Synonyms:
(RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid
2-(difluoromethyl)ornithine
2-(difluoromethyl)ornithine (DMFO)|difluoromethylornithine|Ornidyl®|Vaniqa®
a-(Difluoromethyl)-DL-ornithine
a-Difluoromethylornithine
alpha Difluoromethyl ornithine
alpha Difluoromethylornithine
alpha-(Difluoromethyl)-DL-ornithine
alpha-Difluoromethyl ornithine
alpha-Difluoromethylornithine
DFMO
Difluoromethylornithine
DL alpha Difluoromethylornithine
DL-alpha-Difluoromethylornithine
|
Eflornithine
Eflornithine hydrochloride
Eflornithine monohydrochloride, monohydrate
Hydrochloride, eflornithine
MDL 71,782 a
MDL71,782 a
MDL-71,782 a
Monohydrochloride, monohydrate eflornithine
Ornidyl
Ornithine, alpha-difluoromethyl
Vaniqa
Women first brand OF eflornithine hydrochloride
Α-(difluoromethyl)-DL-ornithine
Α-difluoromethylornithine
|
|
7 |
|
Lomustine |
Approved, Investigational |
Phase 3 |
|
13010-47-4 |
3950 |
Synonyms:
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-Chloroethyl)-3-cyclohexylnitrosourea
Belustine
Bristol myers squibb brand OF lomustine
Bristol-myers squibb brand OF lomustine
CCNU
CCN-U
Cecenu
CeeNU
Chloroethylcyclohexylnitrosourea
CINU
|
Cyclohexyl chloroethyl nitrosourea
Gleostine
Lomustina
LOMUSTINE
Lomustine medac brand
Lomustinum
Medac brand OF lomustine
N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea
NSC-79037
Rhône poulenc rorer brand OF lomustine
Rhône-poulenc rorer brand OF lomustine
|
|
8 |
|
Bevacizumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
9 |
|
Fluorouracil |
Approved |
Phase 2, Phase 3 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
10 |
|
Ornithine |
Approved, Nutraceutical |
Phase 3 |
|
3184-13-2, 70-26-8 |
6262 |
Synonyms:
(+)-S-ORNITHINE
(2S)-2,5-DIAMINOPENTANOIC ACID
(S)-2,5-DIAMINOPENTANOATE
(S)-2,5-DIAMINOPENTANOIC ACID
(S)-2,5-Diaminovalerate
(S)-2,5-DIAMINOVALERIC ACID
(S)-A,D-DIAMINOVALERATE
(S)-A,D-DIAMINOVALERIC ACID
(S)-a,delta-Diaminovalerate
(S)-a,delta-Diaminovaleric acid
(S)-a,Δ-diaminovalerate
(S)-a,Δ-diaminovaleric acid
(S)-alpha,delta-Diaminovalerate
(S)-ALPHA,DELTA-DIAMINOVALERIC ACID
(S)-ORNITHINE
(S)-Α,δ-diaminovalerate
(S)-Α,Δ-DIAMINOVALERIC ACID
2,5 Diaminopentanoic acid
2,5-Diaminopentanoic acid
5-AMINO-L-NORVALINE
|
L-(-)-ORNITHINE
levo-ornithine
L-Ornithine
ORNITHINE
Ornithine dihydrochloride, (L)-isomer
Ornithine hydrochloride, (D)-isomer
Ornithine hydrochloride, (DL)-isomer
Ornithine hydrochloride, (L)-isomer
Ornithine monoacetate, (L)-isomer
Ornithine monohydrobromide, (L)-isomer
Ornithine monohydrochloride, (D)-isomer
Ornithine monohydrochloride, (DL)-isomer
Ornithine phosphate (1:1), (L)-isomer
Ornithine sulfate (1:1), (L)-isomer
Ornithine, (D)-isomer
Ornithine, (DL)-isomer
Ornithine, (L)-isomer
Ornithinum
Ornitina
|
|
11 |
|
Semustine |
Experimental, Investigational |
Phase 3 |
|
13909-09-6 |
5198 |
Synonyms:
1-(2-Chloroethyl)-1-([(4-methylcyclohexyl)amino]carbonyl)-2-oxohydrazine
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea
ICIG 1110
ICIG-1110
Me ccnu
Me-ccnu
MeCCNU
|
Methyl ccnu
Methyl-ccnu
N-(2-Chloroethyl)-n'-(4-methylcyclohexyl)-N-nitrosourea
Semustina
Semustine
Semustinum
|
|
12 |
|
Trabedersen |
Investigational |
Phase 3 |
|
925681-61-4 |
|
Synonyms:
A-12009 FREE ACID
DNA, D(P-THIO)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A)
|
|
|
13 |
|
Interferon-alpha |
|
Phase 3 |
|
|
|
14 |
|
Anticonvulsants |
|
Phase 3 |
|
|
|
15 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
16 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
17 |
|
Antiprotozoal Agents |
|
Phase 3 |
|
|
|
18 |
|
Antiparasitic Agents |
|
Phase 3 |
|
|
|
19 |
|
Immunoglobulin G |
|
Phase 2, Phase 3 |
|
|
|
20 |
|
Endothelial Growth Factors |
|
Phase 2, Phase 3 |
|
|
|
21 |
|
Antineoplastic Agents, Immunological |
|
Phase 2, Phase 3 |
|
|
|
22 |
|
Mitogens |
|
Phase 3 |
|
|
|
23 |
|
Angiogenesis Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
24 |
|
Iodine |
Approved, Investigational |
Phase 2 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
25 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
26 |
|
Carmustine |
Approved, Investigational |
Phase 2 |
|
154-93-8 |
2578 |
Synonyms:
1,3-Bis(2-chloroethyl)-1-nitrosourea
BCNU
Bicnu
BICNU (TN)
Bischlorethylnitrosourea
Bischlorethylnitrosurea
Bischloroethyl nitrosourea
BIS-CHLOROETHYLNITROSOUREA
Carmustin
Carmustina
CARMUSTINE
|
Carmustinum
CARUSTINE
DTI-015
FDA-0345
FIVB
Gliadel
N,N'-bis(2-chloroethyl)-N-nitrosourea
Nitrumon
NSC-409962
SK-27702
SRI-1720
|
|
27 |
|
Leflunomide |
Approved, Investigational |
Phase 2 |
|
75706-12-6 |
3899 |
Synonyms:
5-Methylisoxazole-4-carboxylate (4-trifluoromethyl)anilide
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
a,a,a-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
ARABLOC
Arabloc®|Arava®|HWA 486|HWA-486|lefunamide|SU-101
Arava
Aventis behring brand OF leflunomide
Aventis brand OF leflunomide
Aventis pharma brand OF leflunomide
Hoechst brand OF leflunomide
HWA 486
HWA-486
|
L04AA13
Leflunomida
LEFLUNOMIDE
Léflunomide
Leflunomidum
Leflunomidum [INN-Latin]
LEFUNAMIDE
LEFUNOMIDE
Lefunomide [INN-Spanish]
N-(4-Trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide
SU101
SU-101
SULOL
Α,α,α-trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
|
|
28 |
|
Topotecan |
Approved, Investigational |
Phase 2 |
|
123948-87-8, 119413-54-6 |
60699 60700 |
Synonyms:
9 Dimethylaminomethyl 10 hydroxycamptothecin
9-[(Dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-Dimethylaminomethyl-10-hydroxycamptothecin
Hycamptamine
HYCAMPTIN
Hycamtamine
Hycamtin
Hydrochloride, nogitecan
Hydrochloride, topotecan
Nogitecan hydrochloride
NSC-609699
Potactasol
SK And F 104864 a
SK And F104864a
SK And F-104864-a
|
SK&F-S-104864A
SKF-104864
SK-S-104864-A
SmithKline beecham brand OF topotecan hydrochloride
Topotecan
TOPOTECAN HCL
Topotecan hydrochloride
Topotecan lactone
Topotecan monohydrochloride, (S)-isomer
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
TPT
TTC
|
|
29 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
30 |
|
Cisplatin |
Approved |
Phase 2 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
31 |
|
Aflibercept |
Approved |
Phase 2 |
|
862111-32-8 |
124490314 |
Synonyms:
AFLIBERCEPT
AFLIBERCEPT (GENETICAL RECOMBINATION)
AVE0005
AVE-0005
BAY86-5321
BAY-865321
|
BAY-86-5321
EYLEA
VEGF TRAP
VEGF TRAP-EYE
ZALTRAP
ZIV-AFLIBERCEPT
|
|
32 |
|
Lapatinib |
Approved, Investigational |
Phase 1, Phase 2 |
|
231277-92-2, 388082-78-8 |
208908 |
Synonyms:
FMM
FMM|GW 572016|GW572016|Tykerb®|Tyverb®
GSK-572016
GW 572016
GW-2016
GW572016
GW-572016
GW572016F
GW-572016F
GW-572016X
LAP016
LAPATINIB
LAPATINIB DITOLUENESULFONATE MONOHYDRATE
|
Lapatinib ditosylate
LAPATINIB DITOSYLATE MONOHYDRATE
Lapatinib tosilate hydrate
N-(3-Chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURANYL]-4-QUINAZOLINAMINE
Tycerb
Tykerb
TYVERB
|
|
33 |
|
Romidepsin |
Approved, Investigational |
Phase 1, Phase 2 |
|
128517-07-7 |
5352062 |
Synonyms:
ANTIBIOTIC FR 901228
CHROMADAX
DEPSIPEPTIDE
FK228
FK-228
FK228|FR901228|Istodax®
FR901228
|
FR-901228
ISTODAX
NSC-630176
ROMIDEPSIN
Romidepsina
Romidepsine
Romidepsinum
|
|
34 |
|
Gefitinib |
Approved, Investigational |
Phase 1, Phase 2 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
35 |
|
Mercaptopurine |
Approved |
Phase 2 |
|
50-44-2 |
667490 |
Synonyms:
1,7-Dihydro-6H-purine-6-thione
3H-Purine-6-thiol
6 Mercaptopurine
6 Mercaptopurine monohydrate
6 MP
6 Thiohypoxanthine
6 Thiopurine
6-Mercaptopurine
6-Mercaptopurine monohydrate
6-MP
6-Thiohypoxanthine
6-Thiopurine
6-Thioxopurine
Glaxo wellcome brand OF 6 mercaptopurine
Glaxo wellcome brand OF 6-mercaptopurine
GlaxoSmithKline brand OF 6 mercaptopurine
GlaxoSmithKline brand OF 6-mercaptopurine
Ismipur
Leukerin
Leupurin
Mercaleukim
|
Mercaleukin
Mercaptopurina
Mercaptopurina wellcome
MERCAPTOPURINE
Mercaptopurine anhydrous
MERCAPTOPURINE HYDRATE
Mercaptopurine monohydrate
Mercaptopurinum
Mercapurin
Mern
MP
NSC-755
Puri nethol
Purimethol
Purinethol
Puri-nethol
PURIXAN
Wellcome brand OF 6 mercaptopurine
Wellcome brand OF 6-mercaptopurine
XALUPRINE
|
|
36 |
|
Streptozocin |
Approved, Investigational |
Phase 2 |
|
18883-66-4, 66395-18-4 |
29327 |
Synonyms:
2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose
2-Deoxy-2-((methylnitrosoamino)carbonyl)amino-D-glucose
2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose
Estreptozocina
N-D-Glucosyl-(2)-n'
N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff
N-D-Glucosyl-(2)-n'-nitrosomethylurea
-nitrosomethylharnstoff
NSC-37917
NSC-85998
Streptozocin
|
Streptozocin teva brand
Streptozocine
Streptozocinium
Streptozocinum
Streptozotocin
Streptozotocine
STZ
Teva brand OF streptozocin
U-9889
Zanosar
|
|
37 |
|
Nintedanib |
Approved |
Phase 2 |
|
656247-17-5 |
135423438 9809715 |
Synonyms:
BIBF 1120
BIBF1120
BIBF-1120
BIBF-1120|BIBF1120|Ofev®|Vargatef®
INTEDANIB
|
METHYL (3Z)-3-[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}ANILINO)(PHENYL)METHYLIDENE]-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE
NINTEDANIB
Nintedanib esylate
Ofev
Vargatef
|
|
38 |
|
Dimethyl sulfoxide |
Approved, Vet_approved |
Phase 2 |
|
67-68-5 |
679 |
Synonyms:
(CH3)2SO
(Methylsulfinyl)methane
DIMETHYL SULFOXIDE
Dimethyl sulfoxixde
Dimethyl sulfur oxide
Dimethyl sulphoxide
Dimethyl sulphur oxide
Dimethyl sulpoxide
Dimethyli sulfoxidum
Dimethyli sulphoxidum
Dimethylsulfoxid
Dimethylsulfoxide
Dimethylsulfoxyde
Diméthylsulfoxyde
Dimethylsulphinyl
Dimethylsulphoxid
Dimethylsulphoxide
Dimethylsulphoxyde
Dimetil sulfoxido
Dimetil sulfóxido
Dimetil sulphoxido
Dimexide
DMSO
DOMOSO
|
INFILTRINA
Merckle brand OF dimethyl sulfoxide
Methylsulfinylmethane
Methylsulphinylmethane
NSC-763
Research ind. corp. brand 1 OF dimethyl sulfoxide
Research ind. corp. brand 2 OF dimethyl sulfoxide
Rheumabene
Rimso
rimso 100
Rimso 50
Rimso50
Rimso-50
S(O)Me2
Sclerosol
Shire brand OF dimethyl sulfoxide
SQ-9453
Sulfinylbis(methane)
Sulfoxide, dimethyl
Sulphinylbis(methane)
Sulphoxide, dimethyl
SYNTEXAN
Zymso
|
|
39 |
|
Etoposide |
Approved |
Phase 2 |
|
33419-42-0 |
36462 |
Synonyms:
(-)-Etoposide
(−)-ETOPOSIDE
(-)-etoposide|Etopophos®|Toposar®|trans-etoposide|VePesid®|VP 16-213|VP-16
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
alpha-D-Glucopyranosyl isomer etoposide
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
Celltop
Demethyl epipodophyllotoxin ethylidine glucoside
Eposide
Eposin
Eto gry
Eto-gry
Etomedac
Etopophos
Etopos
ETOPOSIDE
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
|
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
Lastet
Lemery brand OF etoposide
Medac brand OF etoposide
Novartis brand OF etoposide
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Riboposid
Ribosepharm brand OF etoposide
Sanfer brand OF etoposide
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Teva, etoposide
Toposar
trans-Etoposide
Vepesid
Vepesid J
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16-213
VP-16
VP-16-213
Zuyeyidal
|
|
40 |
|
Valaciclovir |
Approved, Investigational |
Phase 1, Phase 2 |
|
124832-27-5, 124832-26-4 |
60773 135398742 |
Synonyms:
2-((2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl L-valinate
256U87 HCL
Acyclovir, L-valyl ester
L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine
L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester
L-Valylacyclovir
Valaciclovir
VALACICLOVIRUM
Valacyclover hydrochloric
Valacyclovir
|
Valacyclovir hydrochloride
VALACYCLOVIR HYDROCHLORIDE (MONOHYDRATE)
Valacyclovir hydrochloride, (DL)-isomer
Valacyclovir, (D)-isomer
Valacyclovir, (DL)-isomer
Valacyclovir, (L)-isomer
Valacyclovir, X-hydrochloride, (D)-isomer
Valacyclovir, X-hydrochloride, (DL)-isomer
Valtrex
ZELITREX
|
|
41 |
|
Sodium citrate |
Approved, Investigational |
Phase 1, Phase 2 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
42 |
|
Mebendazole |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
31431-39-7 |
4030 |
Synonyms:
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamate methyl ester
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
Abello farmacia brand OF mebendazole
Anti worm
Anti-worm
Ardeypharm brand OF mebendazole
Bantenol
Banworm
Boots brand OF mebendazole
Boots threadworm treatment
Degort's brand OF mebendazole
Diba brand OF mebendazole
Elfar brand OF mebendazole
EMVERM
Esteve brand OF mebendazole
Healthypharm brand OF mebendazole
Janssen brand OF mebendazole
Leidapharm brand OF mebendazole
Lomper
Madicure
MBDZ
Mebendan
Mebendazol
Mebendazole
|
Mébendazole
MEBENDAZOLE POLYMORPH C
Mebendazolum
Mebenvet
Norgine brand OF mebendazole
NSC-184849
OVEX
Pfizer brand OF mebendazole
Pripsen mebendazole
R-17635
Sqworm
SSL Brand OF mebendazole
Streger brand OF mebendazole
Sufil
Surfont
Taxandria brand OF mebendazole
Tedec meiji brand OF mebendazole
Telmin
TELMINTIC
Vermicol
Vermidil
Vermin
Vermox
Wormkuur
|
|
43 |
|
Piperazine |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
110-85-0 |
4837 |
Synonyms:
1,4 Diazacyclohexane
1,4 Piperazine
1,4-Diazacyclohexane
1,4-Piperazine
Diethylenediamine
Diethyleneimine
Fluphenazine dihydrochloride
Hexahydropyrazine
Piperazidine
Piperazin
Piperazina
Piperazine
Piperazine diacetate
Piperazine dihydrochloride
Piperazine hexahydrate
|
Piperazine hydrate
Piperazine hydrobromide
Piperazine hydrochloride
Piperazine monohydrochloride
Piperazine phosphate
Piperazine phosphate (1:1)
Piperazine phosphate anhydrous
Piperazine salt
Piperazine sulfate
Piperazine tartrate
Piperazine tartrate (1:1), (R-(r*,r*))-isomer
Piperazine tartrate, (R-(r*,r*))-isomer
Piperazinium oleate
Pripsen
Vermizine
|
|
44 |
|
Pembrolizumab |
Approved |
Phase 1, Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
45 |
|
Vincristine |
Approved, Investigational |
Phase 2 |
|
2068-78-2, 57-22-7 |
5978 |
Synonyms:
(+)-Vincristine
22-OXOVINCALEUKOBLASTIN
22-oxo-Vincaleukoblastine
22-Oxovincaleukoblastine
22-oxovincaleukoblastine|kyocristine|leurocristine sulfate|NSC-67574|Oncovin®
37231
Cellcristin
Citomid
Farmistin
Indole alkaloid
KYOCRISTINE
LCR
Leucristine
Leurocristine
LEUROCRISTINE SULFATE
LILLY-37231
Marqibo
MARQIBO KIT
NSC-67574
Onco TCS
Oncovin
Oncovine
Onkocristin
PFS, Vincasar
|
Sulfate, vincristine
Tecnocris
VCR
VIN
Vincasar
Vincasar PFS
VINCREX
Vincristin
Vincristin bristol
Vincristin medac
Vincristina
Vincristina [DCIT]
VINCRISTINE
Vincristine sulfate
VINCRISTINE SULFATE PFS
VINCRISTINUM
Vincristinum [INN-Latin]
Vincrisul
Vincrstine
Vincrystine
Vinkristin
Vintec
Z-D-Val-lys(Z)-OH
|
|
46 |
|
Sorbitol |
Approved, Investigational |
Phase 1, Phase 2 |
|
69-65-8, 50-70-4 |
453 6251 5780 |
Synonyms:
(-)-Sorbitol
(−)-SORBITOL
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5S)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
7B5697N
ALEXITOL SODIUM
ARIDOL KIT
Baxter brand OF sorbitol
Bronchitol
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-(-)-Sorbitol
D-(−)-SORBITOL
D-Glucitol
Diakarmon
Diosmol
D-Mannitol
D-Sorbit
D-SORBITOL
D-Sorbol
Dulcite
e 420
e 421
e420
e-420
e421
e-421
Esasorb
FEMA NO. 3029
Foodol D 70
FRAXININE
GLC-Ol
Glucarine
Glucitol
g-Ol
Hexahydroxyhexane
Hexanhexol
INS NO.421
INS-421
Invenex
ISOMALT IMPURITY, MANNITOL-
ISOMALT IMPURITY, SORBITOL-
Isotol
Karion
Karion instant
Klysma sorbit
Kyowa powder 50m
L-Gulitol
Manicol
MANITOL
Maniton S
Maniton-S
Manna sugar
Mannazucker
Mannidex
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
MANNITOLUM
|
Mannogem 2080
Marine crystal
Medefield brand OF sorbitol
Medevac
Multitol
Mushroom sugar
Neosorb
Neosorb 20/60dC
Neosorb 70/02
Neosorb 70/70
Neosorb p 20/60
Neosorb p 60
Neosorb p 60W
Nivitin
NSC-25944
NSC-407017
Osmitrol
Osmofundin
Osmosal
Pfizer brand OF sorbitol
Resectisol
Resulax
SDM No. 35
Sionit
Sionit K
Sionite
Sionon
Siosan
Sorbex m
Sorbex R
Sorbex RP
Sorbex S
Sorbex X
Sorbilande
Sorbilax
Sorbit
Sorbit D 70
Sorbit DP
Sorbit DP 50
Sorbit D-powder
Sorbit kyowa powder 50m
Sorbit L 70
Sorbit S
Sorbit T 70
Sorbit W 70
Sorbit WP
Sorbit W-powder
Sorbit W-powder 50
Sorbite
SORBITOL
Sorbitol 3% in plastic container
Sorbitol F
Sorbitol FK
Sorbitol FP
Sorbitol pfizer brand
Sorbitol S
Sorbitol syrup C
Sorbitur
Sorbo
Sorbogem 712
Sorbol
Sorbostyl
Tobrex
Trommsdorff brand OF sorbitol
Yal
|
|
47 |
|
Carboplatin |
Approved |
Phase 1, Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
48 |
|
Cetuximab |
Approved |
Phase 1, Phase 2 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
49 |
|
Palbociclib |
Approved, Investigational |
Phase 2 |
|
571190-30-2 |
5330286 |
Synonyms:
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-D)pyrimidin-7-one
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-{[5-(PIPERAZIN-1-YL)PYRIDIN-2-YL]AMINO}PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
IBRANCE
Ibrance®|PD-0332991|PD0332991
PALBOCICLIB
|
PD 0332991
PD 332991
PD0332991
PD-0332991
UNII-g9Zf61le7g
|
|
50 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
Interventional clinical trials:
(show top 50)
(show all 193)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) |
Recruiting |
NCT03975829 |
Phase 4 |
dabrafenib;trametinib |
2 |
Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma |
Unknown status |
NCT01656980 |
Phase 3 |
Carmustine |
3 |
A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma |
Unknown status |
NCT03633552 |
Phase 3 |
Temozolomide |
4 |
A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas |
Unknown status |
NCT01765088 |
Phase 3 |
Temozolomide;α-IFN |
5 |
A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma |
Completed |
NCT00335075 |
Phase 3 |
Temozolomide;Semustine |
6 |
A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) |
Completed |
NCT00004259 |
Phase 3 |
BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles |
7 |
NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide |
Completed |
NCT00717210 |
Phase 3 |
Temozolomide |
8 |
Radiotherapy for Malignant Astrocytomas in the Elderly |
Completed |
NCT00430911 |
Phase 3 |
Radiotherapy |
9 |
Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) |
Completed |
NCT01502241 |
Phase 3 |
Temozolomide |
10 |
A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment |
Recruiting |
NCT02629757 |
Phase 3 |
β-elemene |
11 |
International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) |
Recruiting |
NCT03243461 |
Phase 3 |
Temozolomide + Valproic Acid |
12 |
A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy |
Active, not recruiting |
NCT02796261 |
Phase 3 |
Eflornithine;Lomustine |
13 |
A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas |
Active, not recruiting |
NCT01236560 |
Phase 2, Phase 3 |
Temozolomide;Vorinostat |
14 |
Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study. |
Terminated |
NCT00761280 |
Phase 3 |
trabedersen;temozolomide;carmustine;lomustine |
15 |
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma |
Terminated |
NCT02414165 |
Phase 2, Phase 3 |
Toca FC;Lomustine;Temozolomide |
16 |
A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma |
Withdrawn |
NCT04105374 |
Phase 2, Phase 3 |
Extended Release Flucytosine;Temozolomide |
17 |
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma |
Unknown status |
NCT00114309 |
Phase 2 |
131-I-TM-601;131I-TM601 |
18 |
Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas |
Unknown status |
NCT01721577 |
Phase 1, Phase 2 |
AXL1717 |
19 |
A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients |
Completed |
NCT01462695 |
Phase 2 |
Sunitinib Malate |
20 |
A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG) |
Completed |
NCT01514201 |
Phase 1, Phase 2 |
Temozolomide;Veliparib |
21 |
SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma |
Completed |
NCT00783393 |
Phase 2 |
Temozolomide |
22 |
A Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma (Defined for the Purposes of the Protocol as Anaplastic Astrocytoma [AA] or Glioblastoma Multiforme [GBM]) Using the Litxâ„¢ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma |
Completed |
NCT00409214 |
Phase 2 |
LS11 (talaporfin sodium) |
23 |
A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse |
Completed |
NCT00003775 |
Phase 2 |
leflunomide |
24 |
A Phase II Trial of Paclitaxel and Topotecan With Filgrastim in Patients With Recurrent or Refractory Glioblastoma Multiforme or Anaplastic Astrocytoma |
Completed |
NCT00002814 |
Phase 2 |
paclitaxel;topotecan hydrochloride |
25 |
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme |
Completed |
NCT00606008 |
Phase 2 |
Sunitinib Malate |
26 |
Phase II Trial of Pre-Irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma) |
Completed |
NCT00003621 |
Phase 2 |
carmustine;cisplatin;etoposide |
27 |
Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma |
Completed |
NCT00003470 |
Phase 2 |
Antineoplaston therapy (Atengenal + Astugenal) |
28 |
A Phase II Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Anaplastic Astrocytoma or Recurrent Glioblastoma Multiforme |
Completed |
NCT00921167 |
Phase 2 |
Bevacizumab/Irinotecan |
29 |
Phase I/II Trial of Oral Erlotinib (Tarceva, OSI-774) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma |
Completed |
NCT00301418 |
Phase 1, Phase 2 |
Erlotinib |
30 |
Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma |
Completed |
NCT00003537 |
Phase 2 |
Antineoplaston therapy (Atengenal + Astugenal) |
31 |
BPA-Mediated Boron Neutron Capture Therapy (BNCT) in the Treatment of Glioblastoma or Anaplastic Astrocytoma Progressing After Conventional External Beam Radiotherapy |
Completed |
NCT00115440 |
Phase 1, Phase 2 |
|
32 |
Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma |
Completed |
NCT02942264 |
Phase 1, Phase 2 |
Zotiraciclib (TG02);Temozolomide (TMZ) |
33 |
Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma |
Completed |
NCT00679354 |
Phase 2 |
cilengitide |
34 |
Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week |
Completed |
NCT00431561 |
Phase 2 |
AP 12009 10 µM;AP 12009 80 µM;temozolomide or PCV |
35 |
A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma) |
Completed |
NCT00823797 |
Phase 2 |
Bendamustine Hydrochloride |
36 |
A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage |
Completed |
NCT00492089 |
Phase 2 |
bevacizumab;placebo |
37 |
A Phase 2 Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas |
Completed |
NCT00667394 |
Phase 2 |
MLN-518 (Tandutinib) |
38 |
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
Completed |
NCT00499473 |
Phase 2 |
sunitinib malate |
39 |
Phase II Study of Bevacizumab Plus Irinotecan (Camptosarâ„¢) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas |
Completed |
NCT00381797 |
Phase 2 |
Irinotecan Hydrochloride |
40 |
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
Completed |
NCT00369590 |
Phase 2 |
|
41 |
A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas |
Completed |
NCT00085540 |
Phase 1, Phase 2 |
depsipeptide |
42 |
Pre-operative IL13-PE38QQR Infusion in Patients With Recurrent or Progressive Supratentorial Malignant Glioma: A Phase I/II Study |
Completed |
NCT00041587 |
Phase 1, Phase 2 |
IL13-PE38QQR |
43 |
A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas |
Completed |
NCT00879437 |
Phase 2 |
Valproic acid;Bevacizumab |
44 |
Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma |
Completed |
NCT00095940 |
Phase 1, Phase 2 |
lapatinib ditosylate |
45 |
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas |
Completed |
NCT00995007 |
Phase 2 |
ZD6474 (Vandetanib);Carboplatin |
46 |
Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma |
Completed |
NCT00112736 |
Phase 1, Phase 2 |
erlotinib;temsirolimus |
47 |
Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors |
Completed |
NCT00042991 |
Phase 1, Phase 2 |
gefitinib |
48 |
Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas |
Completed |
NCT01051557 |
Phase 1, Phase 2 |
Perifosine;Temsirolimus |
49 |
A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy |
Completed |
NCT00045110 |
Phase 1, Phase 2 |
erlotinib hydrochloride |
50 |
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma: Phase I/II Study |
Completed |
NCT00024570 |
Phase 1, Phase 2 |
IL13-PE38QQR |
|